This PERK inhibitor is being explored by scientists at the ALS Therapy Development Institute for its ability to modulate the efficacy of the UPR pathway, thereby protecting against neurotoxicity found to play a role in ALS.
We are in the process of analyzing data produced from a rigorous preclinical survival efficacy study on this small molecule.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
Please give to ALS TDI to help us get promising treatments out of our lab and into people living with ALS.
November 28 is